tochemotherapyratherthantotamoxifen,becausethelatter has already been demonstrated to show no benefit when applied in addition to chemotherapy compared to chemotherapy alone [5] . However, a positive effect of tamoxifen on the maintenance of a chemotherapy response cannot be excluded and has never been tested in a prospectively randomized study. The observations of Metzner et al. [4] indicate that chemotherapy is still a promising treatment option in metastatic melanoma, and should be considered alllinesoftherapyaftertestingforgenemutationsselective for currently available kinase inhibitors. In patients whose tumors harbor no specific gene mutations, chemotherapy could serve as first-line therapy. In patients tested positive for a genetic aberration allowing treatment with targeted agents,chemotherapycouldbeusedassecond-orthird-line therapyfollowingresistanceagainstthekinaseinhibitorsused infirstline.
The major obstacle for chemo-and immunotherapy of metastaticmelanomathathastobeovercomeisthecurrent lack of reliable biomarkers helping to identify patients who are likely to benefit from either therapy. In this regard, the ongoingphaseIIItrialChemoSensMMoftheDermatologic Cooperative Group (DeCOG, ADO) in Germany and Austriainvestigatesamethodo logyofex-vivosensitivityprofiling [6] to allow an individualized, sensitivity-driven polychemotherapy versus DTIC in metastatic melanoma. It should be furthernoticed,thatthismethodologycanalsobeusedtotest targeted therapeutics. If this trial achieves a positive result, chemotherapywillpersistasoneofthemajormainstaysinthe treatmentofmetastaticmelanoma.
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Treatmentofmetastaticmelanomaiscurrentlyundergoinga fulminant change in standards and decision-making. Until now, chemotherapy with dacarbazine (DTIC) served as the therapeutic standard, without any proof of a real benefit in survival.Anyhow,polychemotherapyregimensnevershowed asuperiorsurvivalwhencomparedwithDTICmonochemotherapyinprospectivelyrandomizedtrials [1] .Veryrecently, forthefirsttimeinmorethantwodecadesofclinicaltrialsin metastatic melanoma, two agents, the immunotherapeutic ipilimumab [2] and the kinase inhibitor vemurafinib [3] , demonstrated a significant prolongation of patient survival, andregistrationforbothsubstancesisimminent.Inparticular vemurafinib, which blocks the Ras-Raf-Mek-Erk phosphokinasepathwayintumorscarryingtheBRafV600Emutation, achieved response rates and a prolonged overall survival neverseenbeforeinmetastaticmelanoma.
However, it soon became clear that the proportion of respondingpatientsaswellasthedurationofresponsetothese therapeutics is limited, and resistance mechanisms arise sooner or later during treatment. Moreover, the currently availabletargetedagentsaresuitableforonlyabout50%of metastatic melanoma patients due to the frequencies of the corresponding gene mutations. For this reason, it would be short-sighted to jump to the conclusion that the 'old-fashioned' treatment strategies are completely outdated and of limitedfutureuseinmetastaticmelanoma.Especiallychemotherapycanproducelong-termremissionsofchemosensitive tumors as shown in the report of Metzner and coworkers in this issue of OnkOlOgie [4] . Here, the authors describe a series of 23 patients with advanced metastatic melanoma treated with mono-or polychemotherapy followed by tamoxifenmaintenance,with6(26%)ofthesepatientsshowing median long-term remissions of 8.6 years. The chemotherapyregimensusedcontainedDTIC,BCNU,cisplatinand carboplatin, alone or in combinations. The favorable treatmentoutcomesobservedbytheauthorsarelikelyattributed
